A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1609-1617

  Olesen, Uffe Høgh ^a,b   Thougaard, Annemette V ^b   Jensen, Peter Buhl ^b   Sehested, Maxwell ^a,b  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

N [4 (1 BENZOYL 4 PIPERIDINYL)BUTYL] 3 (3 PYRIDINYL)ACRYLAMIDE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR MODEL; TUMOR XENOGRAFT;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL LINE, TUMOR; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MAXIMUM TOLERATED DOSE; MICE; NAD; NIACIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ORGAN SPECIFICITY; PIPERIDINES; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953408297     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1130     Document Type: Article

References (36)

1. Goldin A, Venditti JM, Kline I, Mantel N. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966;212:1548-50.
2. Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 1969;48:2140-55.
3. Djerassi I, Abir E, Royer GL, Treat CL. Long-term remissions in childhood acute leukemia: use of infrequent infusions of methotrexate; supportive roles of platelet transfusions and citrovorum factor. Clin Pediatr (Phila) 1966;5:502-9.
4. Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-7.
5. Von Hoff DD, Rozencweig M, Louie AC, Bender RA, Muggia FM. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1978;62:233-5.
6. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007;23:164-70. (Pubitemid 46192971)
7. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004;279:50754-63. (Pubitemid 40017813)
8. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009;20:130-8.
9. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42. (Pubitemid 37413486)
10. Olesen UH, Christensen MK, Bjorkling F, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008;367:799-804.
11. Hansen CM, Hansen D, Holm PK, Larsson R, Binderup L. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. Anticancer Res 2000;20:4211-20. (Pubitemid 32143725)
12. Lovborg H, Martinsson P, Gullbo J, Ekelund S, Nygren P, Larsson R. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem Pharmacol 2002;63:1491-8. (Pubitemid 34457965)
13. Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 2009;77:1612-20.
14. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007;19:223-9. (Pubitemid 46386401)
15. Warburg O, Posener K, Negelein E. Ûber den Stoffwechsel der Tumoren. Biochem Z 1924;152:319-44.
16. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008;26:45-51.
17. Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-7. (Pubitemid 40342552)
18. Pishvaian M, Marshall J, Hwang J, et al. A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. 2009 ASCO Annual Meeting. ASCO; 2009.
19. Biedermann E, Hasmann M, Löser R, et al., inventors; Use of vitamin PP compounds. PCT patent WO 99/53920. 1999 21.04.
20. Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008;324:883-93.
21. Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007;282:24574-82. (Pubitemid 47347525)
22. Kirkland JB. Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des 2009;15:3-11.
23. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007;18:415-20.
24. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008;153 Suppl 1:S68-75. (Pubitemid 351340990)
25. Kirkland JB. Niacin status and treatment-related leukemogenesis. Mol Cancer Ther 2009;8:725-32.
26. Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med 1990;87:163-7, 70. (Pubitemid 20041617)
27. Inculet RI, Norton JA, Nichoalds GE, Maher MM, White DE, Brennan MF. Water-soluble vitamins in cancer patients on parenteral nutrition: a prospective study. JPEN J Parenter Enteral Nutr 1987;11:243-9.
28. Stevens HP, Ostlere LS, Begent RH, Dooley JS, Rustin MH. Pellagra secondary to 5-fluorouracil. Br J Dermatol 1993;128:578-80.
29. de Leij L, Postmus PE, Buys CH, et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 1985;45:6024-33.
30. Grauslund M, Thougaard AV, Fuchtbauer A, et al. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIα in vivo. Mol Pharmacol 2007;72:1003-14. (Pubitemid 47481423)
31. Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 2003;31:e73.
32. Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007;130:1095-107. (Pubitemid 47410271)
33. Beauparlant P, Bedard D, Bernier C, et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 2009;20:346-54.
34. Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nussler V, Hasmann M. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006;11:313-21. (Pubitemid 44390171)
35. Gaudineau C, Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun 2004;317:950-6. (Pubitemid 38481464)
36. Watson M, Roulston A, Belec L, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in NAPRT1-deficient tumors. Mol Cell Biol 2009;29:5872-88.